Table 1.
Clinicopathologic characteristics of all patients.
| Characteristics | All (n = 179, %) | No Sarcopenia Group (n = 103, %) | Sarcopenia Group (n = 76, %) | p |
|---|---|---|---|---|
| Age, years | ||||
| Mean ± SD | 57.5 ± 10.6 | 57.8 ± 11.1 | 57.0 ± 9.9 | 0.615 |
| BMI 1, kg/m2 | ||||
| Mean ± SD | 23.6 ± 3.2 | 24.7 ± 3·3 | 22.1 ± 2.3 | <0.001 |
| Normal (18.5−22.9) | 81 (45.3) | 35 (34.0) | 46 (60.5) | <0.001 |
| Overweight (23.0–24.9) | 52 (29.1) | 30 (29.1) | 22 (28.9) | |
| Obesity (≥25.0) | 46 (25.7) | 38 (36.9) | 8 (10.5) | |
| Comorbidities | ||||
| Hypertension | 48 (26.8) | 28 (27.2) | 20 (26.3) | 0.897 |
| Diabetes | 15 (8.4) | 10 (9.7) | 5 (6.6) | 0.455 |
| Dyslipidemia | 21 (11.7) | 15 (14.6) | 6 (7.9) | 0.171 |
| ASA score | 0.080 | |||
| 1 | 63 (35.2) | 31 (30.1) | 32 (42.1) | |
| 2 | 104 (58.1) | 67 (65.0) | 37 (48.7) | |
| 3 | 12 (6.7) | 5 (4.9) | 7 (9.2) | |
| FIGO stage | 0.653 | |||
| IIIA1 | 8 (4.5) | 5 (4.9) | 3 (3.9) | |
| IIIA2 | 6 (3.4) | 4 (3.9) | 2 (2.6) | |
| IIIB | 17 (9.5) | 9 (8.7) | 8 (10.5) | |
| IIIC | 91 (50.8) | 50 (48.5) | 41 (53.9) | |
| IVA | 10 (5.6) | 4 (3.9) | 6 (7.9) | |
| IVB | 47 (26.3) | 31 (30.1) | 16 (21.1) | |
| CA-125, IU/ml | ||||
| Median (range) | 801.0 (5.1–24720.0) | 833.0 (7.0–10000.0) | 793.0 (5.1–24720.0) | 0.829 |
| Primary treatment strategy | 0.046 | |||
| PDS | 135 (75.4) | 72 (69.9) | 63 (82.9) | |
| NAC | 44 (24.6) | 31 (30.1) | 13 (17.1) | |
| Residual tumour after PDS/IDS | 0.336 | |||
| No gross | 114 (63.7) | 67 (65.0) | 47 (61.8) | |
| <1 cm | 44 (24.6) | 26 (25.2) | 18 (23.7) | |
| 1–2 cm | 10 (5.6) | 3 (2.9) | 7 (9.2) | |
| ≥2 cm | 11 (6.1) | 7 (6.8) | 4 (5.3) | |
| Regimen of first-line chemotherapy | 0.368 | |||
| Paclitaxel-Carboplatin | 161 (89.9) | 93 (90.3) | 68 (89.5) | 0.393 |
| Docetaxel-Carboplatin | 14 (7.8) | 9 (8.7) | 5 (6.6) | |
| Paclitaxel-Carboplatin-Bevacizumab | 4 (2.2) | 1 (1.0) | 3 (3.9) | |
| Main cycles of first-line chemotherapy | ||||
| Median (range) | 6 (4–12) | 6 (4–12) | 6 (4–12) | 0.438 |
| 4–6 | 123 (68.7) | 70 (68.0) | 53 (69.7) | |
| 7–9 | 50 (27.9) | 31 (30.1) | 19 (25.0) | |
| 10–12 | 6 (3.4) | 2 (1.9) | 4 (5.3) | |
| Recurrence | 140 (78.2) | 78 (75.7) | 62 (81.6) | 0.349 |
| PSR 2 | 95 (53.1) | 47 (45.6) | 48 (63.2) | 0.031 |
| PRR | 45 (25.1) | 31 (30.1) | 14 (18.4) | |
| Platinum sensitivity | 0.075 | |||
| Platinum-sensitive 3 | 134 (74.9) | 72 (69.9) | 62 (81.6) | |
| Platinum-resistant | 45 (25.1) | 31 (30.1) | 14 (18.4) |
1 In this study, underweight patients (BMI <18.5 kg/m2) were excluded in analysis. 2 PSR was defined as relapse ≥6 months after completion of taxane- and platinum-based chemotherapy, whereas PRR as relapse <6 months.3 In addition to PSR, the patients who completed taxane- and platinum-based chemotherapy and did not experience disease recurrence during at least six months of follow-up period were considered platinum-sensitive. Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IDS, interval debulking surgery; NAC, neoadjuvant chemotherapy; PDS, primary debulking surgery; PRR, platinum-resistant recurrence; PSR, platinum-sensitive recurrence; SD, standard deviation.